Skip to main content

Advertisement

SpringerLink
Log in

Growth hormone deficiency in the transition period: Body composition and gonad function

  • Short Review
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Recombinant GH therapy is normally administered to GH-deficient children in order to achieve a satisfactory height — the main target during childhood and adolescence. However, the role of GH does not end once final height has been reached, but continues during the so-called transition period. In this phase of life, the body undergoes several changes, both physical and psychological, that culminate in adulthood. During this period, GH has a part in numerous metabolic functions. These include the lipid profile, where it increases HDL and reduces LDL, with the global effect of cardiovascular protection. It also has important effects on body composition (improved muscle strength and lean body mass and reduced body fat), the achievement of proper peak bone density, and gonad maturation. Retesting during the transition period, involving measurement of IGF-I plus a provocative test (insulin tolerance test or GHRH + arginine test), is thus necessary to establish any persistent GH deficiency requiring additional replacement therapy. The close cooperation of the medical professionals involved in the patient’s transition from a pediatric to an adult endocrinologist is essential. The aim of this review is to point out the main aspects of GH treatment on body composition, metabolic and gonad functions in the transition period.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Molitch ME. Growth hormone treatment in adults with growth hormone deficiency: the transition. J Endocrinol Invest 2011, 34: 150–4.

    Article  PubMed  CAS  Google Scholar 

  2. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 2008, 29: 535–59.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  3. Salomon F, Cuneo RC, Hesp R, et al. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 1989, 321: 1797–803.

    Article  PubMed  CAS  Google Scholar 

  4. Clayton PE, Cuneo RC, Juul A, Monson JP, Shalet SM, Tauber M; European Society of Paediatric Endocrinology. Consensus statement on the management of the GH-treated adolescent in the transition to adult care. Eur J Endocrinol 2005, 152: 165–70.

    Article  PubMed  CAS  Google Scholar 

  5. Aimaretti G, Ambrosio MR, Di Somma C, et al. Hypopituitarism induced by traumatic brain injury in the transition phase. J Endocrinol Invest 2005, 28: 984–9.

    Article  PubMed  CAS  Google Scholar 

  6. Nguyen VT, Misra M. Transitioning of children with GH deficiency to adult dosing: changes in body composition. Pituitary 2009, 12: 125–35.

    Article  PubMed  CAS  Google Scholar 

  7. Attanasio AF, Shavrikova E, Blum WF, et al; Hypopituitary Developmental Outcome Study Group. Continued growth hormone (GH) treatment after final height is necessary to complete somatic development in childhood-onset GH-deficient patients. J Clin Endocrinol Metab 2004, 89: 4857–62.

    Article  PubMed  CAS  Google Scholar 

  8. Hulthén L, Bengtsson BA, Sunnerhagen KS, Hallberg L, Grimby G, Johannsson G. GH is needed for the maturation of muscle mass and strength in adolescents. J Clin Endocrinol Metab 2001, 86: 4765–70.

    Article  PubMed  Google Scholar 

  9. Hoffman AR, Kuntze JE, Baptista J, et al. Growth hormone (GH) replacement therapy in adult-onset G H deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004, 89: 2048–56.

    Article  PubMed  CAS  Google Scholar 

  10. Maghnie M, Aimaretti G, Bellone S, et al. Diagnosis of GH deficiency in the transition period: accuracy of insulin tolerance test and insulin-like growth factor-I measurement. Eur J Endocrinol 2005, 152: 589–96.

    Article  PubMed  CAS  Google Scholar 

  11. Ghigo E, Aimaretti G, Arvat E, Camanni F. Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults. Endocrine 2001, 15: 29–38.

    Article  PubMed  CAS  Google Scholar 

  12. Gasco V, Corneli G, Beccuti G, et al. Retesting the childhood-onset GH-deficient patient. Eur J Endocrinol; 2008, 159: S45–52.

    Article  PubMed  CAS  Google Scholar 

  13. Veldhuis JD, Roemmich JN, Richmond EJ, et al. Endocrine control of body composition in infancy, childhood, and puberty. Endocr Rev 2005, 26: 114–46.

    Article  PubMed  CAS  Google Scholar 

  14. Johannsson G, Albertsson-Wikland K, Bengtsson BA. Discontinuation of growth hormone (GH) treatment: metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects. Swedish Study Group for Growth Hormone Treatment in Children. J Clin Endocrinol Metab 1999, 84: 4516–24.

    PubMed  CAS  Google Scholar 

  15. Vahl N, Juul A, Jorgensen JO, Orskov H, Skakkebaek NE, Christiansen JS. Continuation of growth hormone (GH) replacement in GH-deficient patients during transition from childhood to adulthood: a two-year placebo-controlled tudy. J Clin Endocrinol Metab 2000, 85: 1874–81.

    Article  PubMed  CAS  Google Scholar 

  16. O’Halloran DJ, Tsatsoulis A, Whitehouse RW, Holmes SJ, Adams JE, Shalet SM. Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency. J Clin Endocrinol Metab 1993, 76: 1344–8.

    PubMed  Google Scholar 

  17. Sartorio A, Ortolani S, Conti A, Cherubini R, Galbiati E, Faglia G. Effects of recombinant growth hormone (GH) treatment on bone mineral density and body composition in adults with childhood onset growth hormone deficiency. J Endocrinol Invest 1996, 19: 524–9.

    Article  PubMed  CAS  Google Scholar 

  18. Vandeweghe M, Taelman P, Kaufman JM. Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males. J Clin Endocrinol Metab 1993, 39: 409–15.

    CAS  Google Scholar 

  19. Conway GS, Szarras-Czapnik M, Racz K, et al; 1369 GHD to GHDA Transition Study Group. Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency. Eur J Endocrinol 2009, 160: 899–907.

    Article  PubMed  CAS  Google Scholar 

  20. Drake WM, Carroll PV, Maher KT, et al. The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth. J Clin Endocrinol Metab 2003, 88: 1658–63.

    Article  PubMed  CAS  Google Scholar 

  21. Shalet SM, Shavrikova E, Cromer M, et al. Effect of growth hormone (GH) treatment on bone in postpubertal GH-deficient patients: a 2-year randomized, controlled, dose-ranging study. J Clin Endocrinol Metab 2003, 88: 4124–9.

    Article  PubMed  CAS  Google Scholar 

  22. Biller B, Sesmilo G, Baum H, Hayden D, Schoenfeld D, Klibanski A. Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset G H deficiency. J Clin Endocrinol Metab 2000, 85: 970–6.

    PubMed  CAS  Google Scholar 

  23. Underwood LE, Attie KM, Baptista J; Genentech Collaborative Study Group. Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study. J Clin Endocrinol Metab 2003, 88: 5273–80.

    Article  PubMed  CAS  Google Scholar 

  24. Andreassen TT, Oxlund H. The effects of growth hormone on cortical and cancellous bone. J Musculoskelet Neuronal Interact 2001, 2: 49–58.

    PubMed  CAS  Google Scholar 

  25. Canalis E. Insulin-like growth factors and osteoporosis. Bone 1997, 21: 215–6.

    Article  PubMed  CAS  Google Scholar 

  26. Rosén T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtsson BA. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 1997, 137: 240–5.

    Article  PubMed  Google Scholar 

  27. Hogler W, Shaw N. Childhood growth hormone deficiency, bone density, structures and fractures: scrutinizing the evidence. Clin Endocrinol (Oxf) 2010, 72: 281–9.

    Article  CAS  Google Scholar 

  28. Hilczer M, Smyczynska J, Stawerska R, Lewinski A. Effects of one-year low-dose growth hormone (GH) therapy on body composition, lipid profile and carbohydrate metabolism in young adults with childhood-onset severe GH deficiency confirmed after completion of growth promotion. Endokrynol Pol 2008, 59: 292–300.

    PubMed  Google Scholar 

  29. Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab 2010, 95: 167–77.

    Article  PubMed  CAS  Google Scholar 

  30. Sartorio A, Molinari E, Riva G, Conti A, Morabito F, Faglia G. Growth hormone treatment in adults with childhood onset growth hormone deficiency: effects on psychological capabilities. Horm Res 1995, 44: 6–11.

    Article  PubMed  CAS  Google Scholar 

  31. Colao A, Di Somma C, Salerno M, Spinelli L, Orio F, Lombardi G. The cardiovascular risk of GH-deficient adolescents. J Clin Endocrinol Metab 2002, 87: 3650–5.

    Article  PubMed  CAS  Google Scholar 

  32. Carroll PV, Drake WM, Maher KT, et al. Comparison of continuation or cessation of growth hormone (GH) therapy on body composition and metabolic status in adolescents with severe G H deficiency at completion of linear growth. J Clin Endocrinol Metab 2004, 89: 3890–5.

    Article  PubMed  CAS  Google Scholar 

  33. Götherström G, Bengtsson BA, Bosaeus I, Johannsson G, Svensson J. A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. J Clin Endocrinol Metab 2007, 92: 1442–5.

    Article  PubMed  CAS  Google Scholar 

  34. Florakis D, Hung V, Kaltsas G, et al. Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study. Clin Endocrinol (Oxf) 2000, 53: 453–9.

    Article  CAS  Google Scholar 

  35. Shimonovitz S, Zacut D, Ben Chetrit A, Ron M. Growth hormone status in patients with maturation arrest of spermatogenesis. Hum Reprod 1993, 8: 919–21.

    PubMed  CAS  Google Scholar 

  36. Gravance CG, Breier BH, Vickers MH, Casey PJ. Impaired sperm characteristics in postpubertal growth-hormone-deficient dwarf (dw/dw) rats. Anim Reprod Sci 1997, 49: 71–6.

    Article  PubMed  CAS  Google Scholar 

  37. Radicioni A, Paris E, Dondero F, Bonifacio V, Isidori A. Recombinant-growth hormone (rec-hGH) therapy in infertile men with idiopathic oligozoospermia. Acta Eur Fertil 1994, 25: 311–7.

    PubMed  CAS  Google Scholar 

  38. Kanzaki M, Morris PL. Growth hormone regulates steroidogenic acute regulatory protein expression and steroidogenesis in Leydig cell progenitors. Endocrinology 1999, 140: 1681–6.

    PubMed  CAS  Google Scholar 

  39. Carani C, Mantovani R, Procopio M, Del Rio G, Rossetto R, Granata AR. GH/IGF-I axis in azoospermia in primary and secondary hypogonadism: a study before and during replacement therapy. Int JAndrol 1999, 22: 184–9.

    Article  CAS  Google Scholar 

  40. Bartke A, Chandrashekar V, Bailey B, Zaczek D, Turyn D. Consequences of growth hormone (GH) overexpression and GH resistance. Neuropeptides 2002, 36: 201–8.

    Article  PubMed  CAS  Google Scholar 

  41. Nakae J, Kido Y, Accili D. Distinct and overlapping functions of insulin and IGF-I receptors. Endocr Rev 2001, 22: 818–35.

    Article  PubMed  CAS  Google Scholar 

  42. Zhou J, Xu BC, Maheshwari HG, et al. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc Natl Acad Sci 1997, 94: 13215–20.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  43. Schneider HJ, Pagotto U, Stalla GK. Central effects of the somatotropic system. Eur J Endocrinol 2003, 149: 377–92.

    Article  PubMed  CAS  Google Scholar 

  44. Codner E, Cassorla F. Growth hormone and reproductive function. Mol Cell Endocrinol 2002, 186: 133–6.

    Article  CAS  Google Scholar 

  45. Chandrashekar V, Bartke A, Coschigano KT, Kopchick JJ. Pituitary and testicular function in growth hormone receptor gene knockout mice. Endocrinology 1999, 140: 1082–8.

    PubMed  CAS  Google Scholar 

  46. Lackey BR, Gray SL, Henricks DM. The insulin-like growth factor (IGF) system and gonadotropin regulation: actions and interactions. Cytokine Growth Factor Rev 1999, 10: 201–17.

    Article  PubMed  CAS  Google Scholar 

  47. Hiney JK, Srivastava V, Nyberg CL, Ojeda SR, Dees WL. Insulin like growth factor I of peripheral origin acts centrally to accelerate the initiation of female puberty. Endocrinology 1996, 137: 3717–28.

    PubMed  CAS  Google Scholar 

  48. Jia XC, Kalmijn J, Hsueh AJ. Growth hormone enhances follicle stimulating hormone-induced differentiation of cultured rat granulosa cells. Endocrinology 1986, 118: 1401–9.

    Article  PubMed  CAS  Google Scholar 

  49. Chuzel F, Clark AM, Avallet O, Saez JM. Transcriptional regulation of the lutropin/human choriogonadotropin receptor and three enzymes of steroidogenesis by growth factors in cultured pig Leydig cells. Eur J Biochem 1996, 239: 8–16.

    Article  PubMed  CAS  Google Scholar 

  50. Mazerbourg S, Bondy CA, Zhou J, Monget P. The insulin-like growth factor system: a key determinant role in the growth and selection of ovarian follicles? A comparative species study. Reprod Domest Anim 2003, 38: 247–58.

    Article  PubMed  CAS  Google Scholar 

  51. Monget P, Fabre S, Mulsant P, et al. Regulation of ovarian folliculogenesis by IGF and BMP system in domestic animals. Domest Anim Endocrinol 2002, 23: 139–54.

    Article  PubMed  CAS  Google Scholar 

  52. Spiliotis BE. Growth hormone insufficiency and its impact on ovarian function. Ann N Y Acad Sci 2003, 997: 77–84.

    Article  PubMed  CAS  Google Scholar 

  53. Leschek EW, Troendle JF, Yanovski JA, et al. Effect of growth hormone treatment on testicular function, puberty, and adrenarche in boys with non-growth hormone-deficient short stature: A randomized, double-blind, placebo-controlled trial. J Pediatr 2001, 138: 406–10.

    Article  PubMed  CAS  Google Scholar 

  54. Ankarberg-Lindgren C, Norjavaara E, Wikland KA. Short boys treated with growth hormone show normal progression of testicular size and achieve normal serum testosterone concentrations. Eur J Endocrinol 2002, 146: 681–5.

    Article  PubMed  CAS  Google Scholar 

  55. Hokken-Koelega A, Van Pareren Y, Arends N, Boonstra V. Efficacy and safety of long-term continuous growth hormone treatment of children born small for gestational age. Horm Res 2004, 62(Suppl 3): 149–54.

    Article  PubMed  CAS  Google Scholar 

  56. Radicioni AF, Paris E, De Marco E, Anzuini A, Gandini L, Lenzi A. Testicular function in boys previously treated with recombinanthuman growth hormone for non-growth hormone-deficient short stature. J Endocrinol Invest 2007, 30: 931–6.

    Article  PubMed  CAS  Google Scholar 

  57. Bertelloni S, Baroncelli GI, Viacava P, Massimetti M, Simi P, Saggese G. Can growth hormone treatment in boys without growth hormone deficiency impair testicular function? J Pediatr 1999, 135: 367–70.

    Article  PubMed  CAS  Google Scholar 

  58. Balducci R, Toscano V, Mangiantini A, Bianchi P, Guglielmi R, Boscherini B. The effect of growth hormone administration on testicular response during gonadotropin therapy in subjects with combined gonadotropin and growth hormone deficiencies. Acta Endocrinol (Copenh) 1993, 128: 19–23.

    CAS  Google Scholar 

  59. Chatelain PG, Sanchez P, Saez JM. Growth hormone and insulinlike growth factor-I treatment increase testicular luteinizing hormone receptors and steroidogenic responsiveness of growth hormone deficient dwarf mice. Endocrinology 1991, 128: 1857–62.

    Article  PubMed  CAS  Google Scholar 

  60. Carani C, Granata A, De Rosa M, et al. The effect of chronic treatment with GH on gonadal function in men with isolated GH deficiency. Eur J Endocrinol 1999, 140: 224–30.

    Article  PubMed  CAS  Google Scholar 

  61. Jørgensen JO, Pedersen SA, Thuesen L, et al. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989, 1: 1221–5.

    Article  PubMed  Google Scholar 

  62. Rutherford OM, Jones DA, Round JM, Buchanan CR, Preece MA. Changes in skeletal muscle and body composition after discontinuation of growth hormone treatment in growth hormone deficient young adults. Clin Endocrinol (Oxf) 1991, 34: 469–75.

    Article  CAS  Google Scholar 

  63. Colle M, Auzerie J. Discontinuation of growth hormone therapy in growth-hormone-deficient patients: assessment of body fat mass using bioelectrical impedance. Horm Res 1993, 39: 192–6.

    Article  PubMed  CAS  Google Scholar 

  64. De Boer H, Van Der Veen EA. Why retest young adults with childhood-onset growth hormone deficiency? J Clin Endocrinol Metab 1997, 82: 2032–6.

    Article  PubMed  Google Scholar 

  65. Savage MO, Drake WM, Carroll PV, Monson JP. Transitional care of GH deficiency: when to stop GH therapy. Eur J Endocrinol 2004, 151: S61–5.

    Article  PubMed  CAS  Google Scholar 

  66. Lanes R, Soros A, Flores K, Gunczler P, Carrillo E, Bandel J. Endothelial function, carotid artery intima-media thickness, epicardial adipose tissue, and left ventricular mass and function in growth hormone-deficient adolescents: apparent effects of growth hormone treatment on these parameters. J Clin Endocrinol Metab 2005, 90: 3978–82.

    Article  PubMed  CAS  Google Scholar 

  67. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Shalet SM, Vance ML; Endocrine Society’s Clinical Guidelines Subcommittee, Stephens PA. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2006, 91: 1621–34.

    Article  PubMed  CAS  Google Scholar 

  68. Wolthers T, Hoffman DM, Nugent AG, Duncan MW, Umpleby M, Ho KK. Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women. Am J Physiol Endocrinol Metab 2001, 281: E1191–6.

    PubMed  CAS  Google Scholar 

  69. Attanasio AF, Lamberts SW, Matranga AM, et al. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. Adult Growth Hormone Deficiency Study Group. J Clin Endocrinol Metab 1997, 82: 82–8.

    PubMed  CAS  Google Scholar 

  70. Radovick S, DiVall S. Approach to the growth hormone-deficient child during transition to adulthood. J Clin Endocrinol Metab 2007, 92: 1195–200.

    Article  PubMed  CAS  Google Scholar 

  71. Saggese G, Baroncelli GI, Vanacore T, Fiore L, Ruggieri S, Federico G. Indications and strategies for continuing GH treatment during transition from late adolescence to early adulthood in patients with GH deficiency: The impact on bone mass. J. Endocrinol Invest 2004, 27: 596–602.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Andrology, Endocrinology, Department of Internal medicine and Applied Biotechnologies, Politechnic University of Marche, Umberto I Hospital, Ancona, Italy

    G. Balercia MD, L. Giovannini, F. Paggi & M. Boscaro

  2. Department of Experimental Medicine, Sapienza University, Rome, Italy

    M. Spaziani, N. Tahani, A. Lenzi & A. Radicioni

Authors
  1. G. Balercia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Giovannini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Paggi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Spaziani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Tahani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Boscaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Lenzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Radicioni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Balercia MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Balercia, G., Giovannini, L., Paggi, F. et al. Growth hormone deficiency in the transition period: Body composition and gonad function. J Endocrinol Invest 34, 709–715 (2011). https://doi.org/10.3275/7804

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.3275/7804

Key-words

Search

Navigation